PaxVax Chikungunya vaccine receives FDA Fast Track designation
by Press Release from Outbreak News Today on (#3PEY3)
PaxVax, a leading independent specialty vaccine company, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its vaccine for the prevention of disease caused by the chikungunya virus. Chikungunya represents a significant public health need and can cause headache, muscle pain, and skin rashes, with severe, ["]
The post PaxVax Chikungunya vaccine receives FDA Fast Track designation appeared first on Outbreak News Today.